Patents by Inventor Changhe Qi

Changhe Qi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZINE COMPOUNDS AND USES THEREOF
    Publication number: 20230135068
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: December 14, 2022
    Publication date: May 4, 2023
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • Triazolo-pyrimidine compounds and uses thereof
    Patent number: 11629147
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 18, 2023
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Qingbei Zeng, Changhe Qi, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Pyrazine compounds and uses thereof
    Patent number: 11571420
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: February 7, 2023
    Assignee: DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
    Inventors: Changhe Qi, Honchung Tsui, Qingbei Zeng, Zhenfan Yang, Xiaolin Zhang
  • PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
    Publication number: 20220402929
    Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Application
    Filed: January 5, 2021
    Publication date: December 22, 2022
    Inventors: Henry Yu, Changhe Qi, Paul Tempest, Selvaraj G. Nataraja, Stephen S. Palmer
  • DNA-DEPENDENT PROTEIN KINASE INHIBITOR
    Publication number: 20220242884
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as DNA-PK inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat DNA-PK related disorder (e.g., cancer).
    Type: Application
    Filed: May 26, 2020
    Publication date: August 4, 2022
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • JAK1 SELECTIVE KINASE INHIBITOR
    Publication number: 20220220096
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).
    Type: Application
    Filed: April 17, 2020
    Publication date: July 14, 2022
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • PYRAZINE COMPOUNDS AND USES THEREOF
    Publication number: 20210251989
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: September 22, 2020
    Publication date: August 19, 2021
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • Pyrazole compounds as modulators of FSHR and uses thereof
    Patent number: 10941152
    Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 9, 2021
    Assignee: ARES TRADING S.A.
    Inventors: Henry Yu, Changhe Qi, Paul Tempest, Selvaraj G. Nataraja, Stephen S. Palmer
  • Pyrazine compounds and uses thereof
    Patent number: 10898481
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: January 26, 2021
    Inventors: Changhe Qi, Honchung Tsui, Qingbei Zeng, Zhenfan Yang, Xiaolin Zhang
  • TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20210009600
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 14, 2021
    Inventors: Qingbei ZENG, Changhe QI, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Triazolo-pyrimidine compounds and uses thereof
    Patent number: 10858365
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: December 8, 2020
    Inventors: Qingbei Zeng, Changhe Qi, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20200331918
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 22, 2020
    Inventors: Qingbei ZENG, Changhe QI, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • PYRAZINE COMPOUNDS AND USES THEREOF
    Publication number: 20200330458
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 22, 2020
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
    Publication number: 20190135823
    Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventors: Henry Yu, Changhe Qi, Paul Tempest, Selvaraj G. Nataraja, Stephen S. Palmer
  • Pyrazole compounds as modulators of FSHR and uses thereof
    Patent number: 10208055
    Abstract: Disclosed are pyrazole compounds, and pharmaceutically acceptable compositions thereof. The compounds and the compositions can be used for positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: February 19, 2019
    Assignee: TOCOPHERX, INC.
    Inventors: Henry Yu, Changhe Qi, Paul Tempest, Selvaraj G. Nataraja, Stephen S. Palmer
  • PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
    Publication number: 20170253605
    Abstract: Disclosed are pyrazole compounds, and pharmaceutically acceptable compositions thereof. The compounds and the compositions can be used for positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Application
    Filed: December 22, 2014
    Publication date: September 7, 2017
    Applicant: TOCOPHERX, INC.
    Inventors: Henry Yu, Changhe Qi, Paul Tempest, Selvaraj G. Nataraja, Stephen S. Palmer
  • Mineralocorticoid receptor antagonists
    Patent number: 9487506
    Abstract: Compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the Formula (I), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the Formula (I) are disclosed.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: November 8, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ping Lan, Kun Liu, Anthony Ogawa, Hong Shen, Christine Yang, Yuguang Wang, Richard Beresis, Changhe Qi
  • Mineralocorticoid receptor antagonists
    Patent number: 9403807
    Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: August 2, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alejandro Crespo, Ping Lan, Rudrajit Mal, Anthony Ogawa, Hong Shen, Peter J. Sinclair, Zhongxiang Sun, Ellen K. Vande Bunte, Zhicai Wu, Kun Liu, Robert J. DeVita, Dong-Ming Shen, Min Shu, John Qiang Tan, Changhe Qi, Yuguang Wang, Richard Beresis
  • Substituted pyridizinone derivatives as PDE10 inhibitors
    Patent number: 9353104
    Abstract: The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 31, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Casey C. McComas, Thomas S. Reger, Changhe Qi
  • MINERALOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20150284376
    Abstract: The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.
    Type: Application
    Filed: December 2, 2014
    Publication date: October 8, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Alejandro Crespo, Ping Lan, Rudrajit Mal, Anthony Ogawa, Hong Shen, Peter J. Sinclair, Zhongxiang Sun, Ellen K. Vande Bunte, Zhicai Wu, Kun Liu, Robert J. DeVita, Dong-Ming Shen, Min Shu, John Qiang Tan, Changhe Qi, Yuguang Wang, Richard Beresis